No abstract

The concurrent think-aloud protocol—in which participants verbalize their thoughts when performing tasks—is a widely employed approach in usability testing. Despite its value, analyzing think-aloud sessions can be onerous because it often entails assessing all of a user's verbalizations. This has motivated previous research on developing categories to segment verbalizations into manageable units of analysis. However, the way in which a category might relate to usability problems is currently unclear. In this research, we sought to address this gap in our understanding. We also studied how speech features might relate to usability problems. Through two studies, this research demonstrates that certain patterns of verbalizations are more telling of usability problems than others and that these patterns are robust to different types of test products (i.e., physical devices and digital systems), access to different types of information (i.e., video and audio modality), and the presence or absence of a visualization of verbalizations. The implication is that the verbalization and speech patterns can potentially reduce the time and effort required for analysis by enabling evaluators to focus more on the important aspects of a user's verbalizations. The patterns could also potentially be used to inform the design of systems to automatically detect when in the recorded think-aloud sessions users experience problems.

Identification of drug targets and mechanism of action (MoA) for new and uncharacterized anticancer drugs is important for optimization of treatment efficacy. Current MoA prediction largely relies on prior information including side effects, therapeutic indication, and chemoinformatics. Such information is not transferable or applicable for newly identified, previously uncharacterized small molecules. Therefore, a shift in the paradigm of MoA predictions is necessary toward development of unbiased approaches that can elucidate drug relationships and efficiently classify new compounds with basic input data. We propose here a new integrative computational pharmacogenomic approach, referred to as Drug Network Fusion (DNF), to infer scalable drug taxonomies that rely only on basic drug characteristics toward elucidating drug-drug relationships. DNF is the first framework to integrate drug structural information, high-throughput drug perturbation, and drug sensitivity profiles, enabling drug classification of new experimental compounds with minimal prior information. DNF taxonomy succeeded in identifying pertinent and novel drug-drug relationships, making it suitable for investigating experimental drugs with potential new targets or MoA. The scalability of DNF facilitated identification of key drug relationships across different drug categories, providing a flexible tool for potential clinical applications in precision medicine. Our results support DNF as a valuable resource to the cancer research community by providing new hypotheses on compound MoA and potential insights for drug repurposing. .

No abstract